Stocks and Investing
Stocks and Investing
Wed, April 25, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Matthew Harrison Maintained (BIIB) at Buy with Increased Target to $369 on, Apr 25th, 2018
Matthew Harrison of Morgan Stanley, Maintained "Biogen Inc." (BIIB) at Buy with Increased Target from $365 to $369 on, Apr 25th, 2018.
Matthew has made no other calls on BIIB in the last 4 months.
There are 7 other peers that have a rating on BIIB. Out of the 7 peers that are also analyzing BIIB, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Geoff Meacham of "Barclays" Downgraded from Buy to Hold on, Thursday, April 5th, 2018
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Hold with Increased Target to $350 on, Wednesday, January 24th, 2018
These are the ratings of the 5 analyists that currently disagree with Matthew
- Ian Somaiya of "BMO Capital" Maintained at Buy with Decreased Target to $393 on, Monday, March 5th, 2018
- Salim Syed of "Mizuho" Maintained at Strong Buy with Increased Target to $433 on, Monday, February 5th, 2018
- Carter Gould of "UBS" Upgraded from Hold to Strong Buy on, Wednesday, January 31st, 2018
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $363 on, Friday, January 26th, 2018
- Jay Olson of "Oppenheimer" Maintained at Buy with Increased Target to $400 on, Friday, January 26th, 2018